BUSICO, ADELE
BUSICO, ADELE
Universita' degli Studi di MILANO
Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care
2023 A. Vingiani, L. Agnelli, M. Duca, D. Lorenzini, S. Damian, C. Proto, M. Niger, F. Nichetti, E. Tamborini, F. Perrone, A. Piccolo, S. Manoukian, J. Azzollini, M. Brambilla, E. Colombo, S. Lopez, C. Vernieri, F. Marra, E. Conca, A. Busico, I. Capone, F. Bozzi, M. Angelini, A. Devecchi, R. Salvatori, V. De Micheli, A. Baggi, S. Pasini, C. Jommi, V. Ladisa, G. Apolone, F. De Braud, G. Pruneri
Safety and antitumor activity of metformin plus lanreotide in patients with advanced gastro-intestinal or lung neuroendocrine tumors: the phase Ib trial MetNET2
2023 S. Pusceddu, F. Corti, N. Prinzi, F. Nichetti, S. Ljevar, A. Busico, T. Cascella, R. Leporati, S. Oldani, C.C. Pircher, J. Coppa, V. Resi, M. Milione, M. Maccauro, R. Miceli, E. Tamborini, F. Perrone, C. Spreafico, M. Niger, F. Morano, F. Pietrantonio, E. Seregni, L. Mariani, V. Mazzaferro, G. Di Liberti, G. Fucà, F. de Braud, C. Vernieri
Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples
2022 I. Capone, F. Bozzi, G.P. Dagrada, P. Verderio, E. Conca, A. Busico, M.A. Testi, V. Monti, M. Duca, C. Proto, S. Damian, A. Piccolo, F. Perrone, E. Tamborini, A. Devecchi, P. Collini, D. Lorenzini, A. Vingiani, L. Agnelli, G. Pruneri
LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial
2020 C. Vernieri, M. Ganzinelli, E. Rulli, G. Farina, A.C. Bettini, C. Bareggi, L. Rosso, D. Signorelli, G. Galli, G. Lo Russo, C. Proto, M. Moro, S. Indraccolo, A. Busico, G. Sozzi, V. Torri, M. Marabese, B. Massimo, M.C. Garassino